Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)?

AtaiBeckley Inc. has been presenting at several June 2026 investor conferences, including the Jefferies Global Healthcare Conference at the Marriott Marquis in New York, to share clinical and ...
Seeking Alpha

AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

The last time I spoke about AtaiBeckley (ATAI), it was with a Seeking Alpha article entitled "Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus." With respect to this ...
Nasdaq

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts ...